IQVIA Holdings Inc. provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Integrated Engagement Services segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company serves pharmaceutical, biotechnology, device and diagnostic, and healthcare companies. IQVIA Holdings Inc. has a strategic alliance with MuleSoft, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
Phone919-998-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.41 million
Profitability
Miscellaneous
Employees55,000
OptionableOptionable
Iqvia (NYSE:IQV) Frequently Asked Questions
What is Iqvia's stock symbol?
Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."
How were Iqvia's earnings last quarter?
Iqvia Holdings Inc (NYSE:IQV) released its quarterly earnings data on Thursday, February, 14th. The medical research company reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.03. The medical research company earned $2.69 billion during the quarter, compared to analyst estimates of $2.62 billion. Iqvia had a return on equity of 14.25% and a net margin of 2.49%. The business's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the prior year, the company posted $1.40 earnings per share. View Iqvia's Earnings History.
When is Iqvia's next earnings date?
What guidance has Iqvia issued on next quarter's earnings?
Iqvia updated its FY19 earnings guidance on Thursday, February, 14th. The company provided earnings per share (EPS) guidance of $6.20-6.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.28. The company issued revenue guidance of $10.9-11.25 billion, compared to the consensus revenue estimate of $10.91 billion.Iqvia also updated its FY 2019 guidance to $6.20-6.40 EPS.
What price target have analysts set for IQV?
16 brokers have issued 12-month price targets for Iqvia's shares. Their predictions range from $120.00 to $170.00. On average, they anticipate Iqvia's stock price to reach $144.80 in the next year. This suggests a possible upside of 3.0% from the stock's current price. View Analyst Price Targets for Iqvia.
What is the consensus analysts' recommendation for Iqvia?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 2 hold ratings, 12 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia.
Has Iqvia been receiving favorable news coverage?
News stories about IQV stock have been trending somewhat negative on Wednesday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Iqvia earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of Iqvia's key competitors?
Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS) and Anavex Life Sciences (AVXL).
Who are Iqvia's key executives?
Iqvia's management team includes the folowing people:
- Mr. Ari Bousbib, Chairman, CEO & Pres (Age 58)
- Mr. Michael R. McDonnell, Exec. VP & CFO (Age 55)
- Mr. W. Richard Staub III, Pres of R&D Solutions (Age 56)
- Mr. Kevin C. Knightly, Pres of Information & Technology Solutions (Age 58)
- Mr. Emmanuel N. Korakis, Corp. Controller & Principal Accounting Officer (Age 45)
Who are Iqvia's major shareholders?
Iqvia's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.49%), Longview Partners Guernsey LTD (4.66%), Oregon Public Employees Retirement Fund (3.57%), Canada Pension Plan Investment Board (2.95%), Geode Capital Management LLC (1.07%) and Brahman Capital Corp. (0.94%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Dennis B Ph D Gillings, Group Holdings (Sbs) Advis Tpg, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks and Ronald A Rittenmeyer. View Institutional Ownership Trends for Iqvia.
Which major investors are selling Iqvia stock?
IQV stock was sold by a variety of institutional investors in the last quarter, including Canada Pension Plan Investment Board, Retirement Systems of Alabama, Longview Partners Guernsey LTD, First Trust Advisors LP, Jarislowsky Fraser Ltd, Two Sigma Investments LP, Bank of America Corp DE and Hsbc Holdings PLC. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks and Ronald A Rittenmeyer. View Insider Buying and Selling for Iqvia.
Which major investors are buying Iqvia stock?
IQV stock was bought by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, USS Investment Management Ltd, Boston Partners, BlackRock Inc., Geode Capital Management LLC, Eagle Asset Management Inc., Dimensional Fund Advisors LP and Third Point LLC. View Insider Buying and Selling for Iqvia.
How do I buy shares of Iqvia?
Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Iqvia's stock price today?
One share of IQV stock can currently be purchased for approximately $140.55.
How big of a company is Iqvia?
Iqvia has a market capitalization of $28.12 billion and generates $10.41 million in revenue each year. The medical research company earns $259 million in net income (profit) each year or $5.12 on an earnings per share basis. Iqvia employs 55,000 workers across the globe.
What is Iqvia's official website?
How can I contact Iqvia?
Iqvia's mailing address is 83 WOOSTER HEIGHTS ROAD, DANBURY CT, 06810. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]
MarketBeat Community Rating for Iqvia (NYSE IQV)
MarketBeat's community ratings are surveys of what our community members think about Iqvia and other stocks. Vote "Outperform" if you believe IQV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IQV will underperform the S&P 500 over the long term. You may vote once every thirty days.
